News
-
Krystal Biotech, which has been developing both injectable and inhaled formulations of its KB707 gene therapy for the treatment of solid tumors, announced that it will now focus on the inhaled therapy for the treatment… Read more . . .
-
According to BiomX, the FDA has placed a clinical hold on the company’s recently-initiated Phase 2b trial of BX004 inhaled phage cocktail in cystic fibrosis patients with chronic P. aeruginosa lung infections. BiomX said that the… Read more . . .
-
According to Boston-based CILA Therapeutics, the company has been awarded an SBIR Phase 1 grant worth almost $380,000 through the NIH’s National Center for Advancing Translational Sciences (NCATS) for pre-clinical development of the company’s CIL-Key… Read more . . .
-
Firebrick Pharma announced that the European Patent Office has accepted the company’s patent application covering the use of povidone-iodine nasal sprays, including Firebrick’s Nasodine, for the reduction of viral load of SARS-CoV-2 in the nose… Read more . . .
-
AstraZeneca has announced the launch of its FluMist Home service for delivery of the FluMist intranasal influenza vaccine in the US for the 2025-26 flu season. In September 2024, the nasal vaccine was approved by the… Read more . . .
-
Proveca and Cessatech have announced the submission of a pediatric-use marketing authorization (PUMA) application for CT001 sufentanil / ketamine nasal spray for the treatment of pain in pediatric patients and said that the EMA has… Read more . . .
-
Copley Scientific has announced the launch of its new Inhalytix+ subscription-based cascade impactor software package. The original Inhalytix software was introduced in 2021. According to the company, the new software can be integrated with testing equipment… Read more . . .
-
According to Tiziana Life Sciences, the FDA has approved the company’s IND for a Phase 2a trial of intranasal foralumab in patients with multiple system atrophy (MSA). The company is currently developing intranasal foralumab for the… Read more . . .
-
MannKind Corporation announced a strategic financing agreement with Blackstone that will provide the company with a $75 million loan initially, with a total potential of up to $500 million. MannKind said that the agreement was made in… Read more . . .
-
Ethris has announced the initiation of a Phase 2a trial of its intranasal ETH47 mRNA-based antiviral in asthma patients. The Phase 2a study is expected to enroll 50 adult patients who will receive either ETH47 or… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA